ICU Medical (ICUI) Financials

$136.12 -5.52 (-3.89%)

As of 03:57 PM Eastern

Annual Income Statements for ICU Medical

This table shows ICU Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	45	63	69	29	101	87	103	-74	-30	-118
Consolidated Net Income / (Loss)	45	63	69	29	101	87	103	-74	-30	-118
Net Income / (Loss) Continuing Operations	45	63	69	29	101	87	103	-74	-30	-118
Total Pre-Tax Income	70	85	51	22	115	97	123	-114	-78	-66
Total Operating Income	69	83	-13	30	107	98	123	-43	23	43
Total Gross Profit	181	201	426	570	472	461	491	698	740	825
Total Revenue	342	379	1,293	1,400	1,266	1,271	1,316	2,280	2,259	2,382
Operating Revenue	341	379	1,293	1,400	1,266	1,271	1,316	2,280	2,259	2,382
Total Cost of Revenue	161	178	867	830	794	810	825	1,582	1,519	1,557
Operating Cost of Revenue	161	178	867	830	794	810	825	1,582	1,519	1,557
Total Operating Expenses	112	118	439	540	365	363	368	741	717	782
Selling, General & Admin Expense	83	89	302	320	277	284	303	608	607	639
Research & Development Expense	16	13	51	53	49	43	47	93	85	89
Restructuring Charge	8.45	15	78	105	81	28	18	71	41	60
Other Special Charges / (Income)	-1.09	0.00	8.00	20	-47	9.00	0.00	-32	-16	-5.40
Total Other Income / (Expense), net	1.13	2.22	65	-7.38	7.35	-0.67	-0.06	-72	-101	-109
Interest Expense	0.04	0.12	2.05	0.71	0.55	-1.92	-1.98	66	95	96
Other Income / (Expense), net	1.17	2.34	67	-6.67	7.90	-2.59	-2.04	-5.14	-5.91	-13
Income Tax Expense	25	22	-17	-6.42	14	11	20	-40	-49	52
Basic Earnings per Share	$2.84	$3.90	$3.50	$1.41	$4.90	$4.16	$4.86	($3.11)	($1.23)	($4.83)
Weighted Average Basic Shares Outstanding	15.85M	16.17M	19.61M	20.39M	20.63M	20.91M	21.21M	23.87M	24.09M	24.39M
Diluted Earnings per Share	$2.73	$3.66	$3.29	$1.33	$4.69	$4.02	$4.74	($3.11)	($1.23)	($4.83)
Weighted Average Diluted Shares Outstanding	16.50M	17.25M	20.86M	21.60M	21.55M	21.59M	21.78M	23.87M	24.09M	24.39M
Weighted Average Basic & Diluted Shares Outstanding	15.80M	16.20M	19.60M	20.40M	20.77M	21.14M	23.79M	24.00M	24.14M	24.52M

This table shows ICU Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-13	-16	-9.81	-9.93	7.24	-17	-39	-21	-33	-24
Consolidated Net Income / (Loss)	-13	-16	-9.81	-9.93	7.24	-17	-39	-21	-33	-24
Net Income / (Loss) Continuing Operations	-13	-16	-9.81	-9.93	7.24	-17	-39	-21	-33	-24
Total Pre-Tax Income	-21	-21	-13	-23	-5.37	-37	-37	-20	-18	8.22
Total Operating Income	-0.47	-0.22	9.40	2.76	23	-12	-11	7.69	8.24	38
Total Gross Profit	186	175	192	192	184	172	185	207	205	227
Total Revenue	598	578	569	549	553	588	567	596	589	630
Operating Revenue	598	578	569	549	553	588	567	596	589	630
Total Cost of Revenue	411	403	377	357	369	416	381	389	384	403
Operating Cost of Revenue	411	403	377	357	369	416	381	389	384	403
Total Operating Expenses	187	175	183	190	161	184	196	200	197	190
Selling, General & Admin Expense	153	143	153	151	149	155	158	160	163	159
Research & Development Expense	23	23	20	22	21	22	22	23	21	22
Restructuring Charge	14	9.63	11	12	7.16	11	16	17	17	9.77
Other Special Charges / (Income)	-4.06	-0.84	-0.70	4.02	-16	-3.99	0.30	-0.34	-3.95	-1.41
Total Other Income / (Expense), net	-21	-21	-23	-26	-28	-24	-26	-27	-26	-29
Interest Expense	18	20	23	24	24	24	24	24	25	23
Other Income / (Expense), net	-3.03	-1.15	-0.27	-1.50	-4.04	-0.09	-2.34	-3.38	-1.48	-6.02
Income Tax Expense	-8.10	-5.91	-3.58	-13	-13	-20	2.70	1.87	15	32
Basic Earnings per Share	($0.55)	($0.64)	($0.41)	($0.41)	$0.30	($0.71)	($1.63)	($0.88)	($1.35)	($0.97)
Weighted Average Basic Shares Outstanding	23.91M	23.87M	24.01M	24.08M	24.13M	24.09M	24.22M	24.39M	24.44M	24.39M
Diluted Earnings per Share	($0.55)	($0.64)	($0.41)	($0.41)	$0.30	($0.71)	($1.63)	($0.88)	($1.35)	($0.97)
Weighted Average Diluted Shares Outstanding	23.91M	23.87M	24.01M	24.08M	24.37M	24.09M	24.22M	24.39M	24.44M	24.39M
Weighted Average Basic & Diluted Shares Outstanding	23.98M	24.00M	24.06M	24.14M	24.14M	24.14M	24.37M	24.43M	24.48M	24.52M

This table details how cash moves in and out of ICU Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	60	109	-155	55	-76	127	157	-344	45	54
Net Cash From Operating Activities	64	90	154	160	102	223	268	-62	166	204
Net Cash From Continuing Operating Activities	64	90	154	160	102	223	268	-62	166	204
Net Income / (Loss) Continuing Operations	45	63	69	29	101	87	103	-74	-30	-118
Consolidated Net Income / (Loss)	45	63	69	29	101	87	103	-74	-30	-118
Depreciation Expense	18	19	67	75	77	86	90	235	229	220
Amortization Expense	1.67	1.36	0.15	0.63	0.42	9.74	10	57	29	28
Non-Cash Adjustments To Reconcile Net Income	16	15	-40	65	82	42	47	56	82	75
Changes in Operating Assets and Liabilities, net	-16	-8.68	59	-8.46	-159	-1.03	18	-336	-144	-0.58
Net Cash From Investing Activities	-11	16	-267	-103	-167	-98	-91	-1,909	-88	-89
Net Cash From Continuing Investing Activities	-11	16	-267	-103	-167	-98	-91	-1,909	-88	-89
Purchase of Property, Plant & Equipment	-13	-23	-74	-93	-97	-92	-69	-90	-84	-79
Acquisitions	-58	-3.78	-168	-9.36	-85	-8.39	-30	-1,853	-9.78	-11
Purchase of Investments	-56	-118	-25	-30	-26	-33	-10	-3.40	0.00	0.00
Sale of Property, Plant & Equipment	3.59	3.27	0.00	14	0.03	6.18	0.22	0.99	1.50	0.75
Sale and/or Maturity of Investments	83	159	0.00	15	41	29	18	36	4.22	0.50
Net Cash From Financing Activities	16	2.47	-44	8.02	-11	-0.04	-17	1,637	-36	-56
Net Cash From Continuing Financing Activities	16	2.47	106	8.02	-11	-0.04	-17	1,637	-36	-56
Repayment of Debt	0.00	0.00	-75	0.00	0.00	-150	0.00	-25	-30	-51
Repurchase of Common Equity	-1.52	-17	-4.06	-6.25	-19	-13	-8.34	-11	-9.35	-12
Issuance of Debt	-	-	-	0.00	0.00	150	0.00	1,664	0.00	0.00
Other Financing Activities, net	15	17	32	14	7.73	13	-8.54	8.11	3.06	7.19
Effect of Exchange Rate Changes	-8.28	0.22	1.79	-10	-0.23	2.85	-3.25	-9.48	3.16	-4.93
Cash Interest Paid	0.04	0.12	2.05	0.71	0.55	1.75	0.86	64	96	100
Cash Income Taxes Paid	23	21	5.11	13	9.68	32	20	28	36	25

This table details how cash moves in and out of ICU Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-12	-35	12	-25	1.31	57	-2.80	51	9.86	-3.95
Net Cash From Operating Activities	2.31	-1.71	41	-1.47	35	91	46	82	36	40
Net Cash From Continuing Operating Activities	2.31	-1.71	41	-1.47	35	91	46	82	36	40
Net Income / (Loss) Continuing Operations	-13	-16	-9.81	-9.93	7.24	-17	-39	-21	-33	-24
Consolidated Net Income / (Loss)	-13	-16	-9.81	-9.93	7.24	-17	-39	-21	-33	-24
Depreciation Expense	59	57	56	58	58	57	56	55	56	53
Amortization Expense	8.30	12	7.36	7.16	7.14	7.07	7.05	6.89	7.18	7.03
Non-Cash Adjustments To Reconcile Net Income	16	16	18	22	16	26	18	17	24	16
Changes in Operating Assets and Liabilities, net	-67	-71	-31	-78	-53	18	4.40	24	-17	-12
Net Cash From Investing Activities	-13	-24	-15	-18	-25	-31	-18	-22	-23	-27
Net Cash From Continuing Investing Activities	-13	-24	-15	-18	-25	-31	-18	-22	-23	-27
Purchase of Property, Plant & Equipment	-21	-22	-14	-18	-21	-30	-16	-19	-20	-24
Acquisitions	-2.12	-2.46	-2.53	-2.12	-3.09	-2.04	-2.95	-2.41	-2.95	-2.52
Sale of Property, Plant & Equipment	0.03	0.06	0.05	1.38	0.05	0.02	0.51	0.19	0.00	0.05
Net Cash From Financing Activities	2.53	-10	-16	-5.90	-6.40	-7.85	-27	-10	-10	-8.19
Net Cash From Continuing Financing Activities	2.53	-10	-16	-5.90	-6.40	-7.85	-27	-10	-10	-8.19
Repayment of Debt	-2.13	-2.45	-7.38	-7.44	-7.44	-7.44	-13	-13	-13	-13
Other Financing Activities, net	4.66	11	-8.46	1.54	1.04	8.94	-14	2.37	2.37	17
Effect of Exchange Rate Changes	-4.13	1.00	1.94	-0.08	-2.95	4.26	-3.88	1.35	7.01	-9.40

This table presents ICU Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	627	705	1,497	1,585	1,692	1,764	1,881	4,516	4,378	4,204
Total Current Assets	505	569	865	927	882	921	1,030	1,235	1,221	1,442
Restricted Cash	-	-	-	-	-	-	-	209	254	309
Short-Term Investments	41	0.00	10	37	24	15	14	4.22	0.50	0.00
Accounts Receivable	57	55	208	176	202	124	106	222	162	183
Inventories, net	44	49	289	311	338	315	290	696	709	585
Prepaid Expenses	7.63	7.36	41	46	34	41	47	89	74	70
Current Deferred & Refundable Income Taxes	14	11	11	11	16	29	20	16	22	11
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	0.00	284
Plant, Property, & Equipment, net	74	86	399	433	456	467	468	636	613	443
Total Noncurrent Assets	47	50	234	226	354	376	383	2,644	2,544	2,319
Goodwill	6.46	5.58	12	11	31	33	43	1,449	1,472	1,433
Intangible Assets	24	22	144	133	211	197	188	983	871	741
Noncurrent Deferred & Refundable Income Taxes	17	22	25	39	28	31	43	31	37	24
Other Noncurrent Operating Assets	-	0.00	38	40	83	102	104	180	164	121
Total Liabilities & Shareholders' Equity	627	705	1,497	1,585	1,692	1,764	1,881	4,516	4,378	4,204
Total Liabilities	47	45	299	322	315	261	265	2,426	2,255	2,239
Total Current Liabilities	43	41	210	249	248	195	201	495	482	556
Short-Term Debt	-	-	-	-	0.00	26	0.00	30	56	51
Accounts Payable	14	15	78	120	129	72	81	216	150	148
Accrued Expenses	29	26	132	129	118	97	118	243	268	307
Current Deferred & Payable Income Tax Liabilities	-	-	-	0.00	2.06	0.30	1.45	6.20	7.71	17
Other Current Nonoperating Liabilities	-	-	-	-	-	-	-	-	0.00	33
Total Noncurrent Liabilities	4.34	4.00	88	72	67	66	64	1,931	1,773	1,683
Long-Term Debt	1.48	1.11	55	21	-	-	-	1,624	1,578	1,532
Noncurrent Deferred Revenue	-	-	-	-	14	16	18	42	35	35
Noncurrent Deferred & Payable Income Tax Liabilities	2.86	2.89	6.08	4.46	2.09	1.66	1.49	126	56	49
Other Noncurrent Operating Liabilities	-	0.00	27	47	50	48	44	140	104	67
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	580	660	1,198	1,264	1,377	1,502	1,616	2,090	2,123	1,965
Total Preferred & Common Equity	580	660	1,198	1,264	1,377	1,502	1,616	2,090	2,123	1,965
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	580	660	1,198	1,264	1,377	1,502	1,616	2,090	2,123	1,965
Common Stock	147	164	628	660	671	695	724	1,334	1,369	1,415
Retained Earnings	454	517	586	621	722	809	912	838	808	690
Treasury Stock	0.00	-0.01	0.00	-0.10	-0.16	-0.04	-0.03	-0.24	-0.26	-0.09
Accumulated Other Comprehensive Income / (Loss)	-21	-21	-15	-17	-15	-1.52	-19	-81	-53	-139

This table presents ICU Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	4,450	4,471	4,463	4,377	4,288	4,287	4,305
Total Current Assets	1,199	1,213	1,245	1,219	1,188	1,236	1,258
Cash & Equivalents	-	-	196	197	251	303	313
Short-Term Investments	2.92	3.24	1.81	1.81	0.00	0.00	0.00
Accounts Receivable	213	139	162	162	145	152	174
Inventories, net	625	748	775	760	693	683	692
Prepaid Expenses	94	87	96	84	83	81	74
Current Deferred & Refundable Income Taxes	20	14	14	15	15	18	5.79
Plant, Property, & Equipment, net	656	624	617	609	603	594	596
Total Noncurrent Assets	2,595	2,633	2,602	2,549	2,498	2,457	2,451
Goodwill	1,370	1,463	1,464	1,444	1,459	1,451	1,478
Intangible Assets	1,021	958	930	891	837	806	786
Noncurrent Deferred & Refundable Income Taxes	15	31	31	31	40	39	41
Other Noncurrent Operating Assets	187	182	176	181	162	161	147
Total Liabilities & Shareholders' Equity	4,450	4,471	4,463	4,377	4,288	4,287	4,305
Total Liabilities	2,438	2,370	2,348	2,279	2,221	2,249	2,256
Total Current Liabilities	489	462	484	464	455	512	550
Short-Term Debt	25	35	42	52	53	53	53
Accounts Payable	205	186	167	149	152	156	169
Accrued Expenses	244	235	255	251	248	300	326
Current Deferred & Payable Income Tax Liabilities	15	5.53	20	11	2.48	4.14	2.77
Total Noncurrent Liabilities	1,949	1,908	1,864	1,814	1,765	1,737	1,707
Long-Term Debt	1,630	1,612	1,601	1,589	1,566	1,555	1,543
Noncurrent Deferred Revenue	20	42	37	40	36	33	35
Noncurrent Deferred & Payable Income Tax Liabilities	154	115	90	78	56	54	49
Other Noncurrent Operating Liabilities	145	139	137	107	107	95	80
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,013	2,100	2,115	2,098	2,068	2,038	2,049
Total Preferred & Common Equity	2,013	2,100	2,115	2,098	2,068	2,038	2,049
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,013	2,100	2,115	2,098	2,068	2,038	2,049
Common Stock	1,326	1,342	1,347	1,359	1,374	1,383	1,397
Retained Earnings	853	828	818	825	768	747	714
Treasury Stock	-0.13	-8.01	-1.61	-0.67	-4.69	-0.52	-0.21
Accumulated Other Comprehensive Income / (Loss)	-166	-62	-49	-85	-70	-92	-62

This table displays calculated financial ratios and metrics derived from ICU Medical's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.48%	11.04%	240.72%	8.31%	-9.56%	0.38%	3.56%	73.21%	-0.92%	5.44%
EBITDA Growth	45.67%	18.11%	13.59%	-17.99%	95.63%	-0.86%	15.95%	10.33%	12.35%	1.09%
EBIT Growth	75.26%	22.29%	-37.47%	-56.72%	399.31%	-17.08%	26.82%	-139.63%	135.23%	75.77%
NOPAT Growth	71.29%	38.83%	-128.96%	315.20%	146.95%	-7.51%	17.97%	-129.10%	153.21%	88.23%
Net Income Growth	70.82%	40.23%	8.81%	-58.05%	250.90%	-14.02%	18.72%	-172.03%	60.08%	-296.86%
EPS Growth	62.50%	34.07%	-10.11%	-59.57%	252.63%	-14.29%	17.91%	-165.61%	60.45%	-292.68%
Operating Cash Flow Growth	-3.23%	40.11%	71.69%	3.75%	-36.39%	118.56%	20.11%	-123.22%	367.51%	22.76%
Free Cash Flow Firm Growth	-94.50%	2,686.21%	-1,601.13%	109.99%	-221.96%	174.80%	143.55%	-1,635.54%	101.73%	1,154.03%
Invested Capital Growth	26.50%	6.04%	334.93%	-3.79%	20.50%	1.86%	-5.49%	238.05%	-0.78%	-14.68%
Revenue Q/Q Growth	3.17%	1.42%	26.95%	-2.08%	-1.93%	0.39%	1.55%	11.63%	0.44%	1.79%
EBITDA Q/Q Growth	0.09%	1.36%	50.48%	-34.54%	21.14%	9.48%	-4.73%	9.12%	-5.29%	16.71%
EBIT Q/Q Growth	0.64%	1.69%	95.89%	-69.47%	40.77%	6.16%	-4.52%	-86.21%	-39.18%	309.36%
NOPAT Q/Q Growth	-4.00%	6.67%	62.82%	-59.44%	30.91%	6.69%	-3.01%	-127.56%	-34.38%	721.77%
Net Income Q/Q Growth	-4.07%	6.86%	141.27%	-66.46%	38.33%	6.76%	-5.69%	-91.34%	-5.74%	-6.02%
EPS Q/Q Growth	-4.55%	5.48%	117.88%	-66.50%	38.35%	6.63%	-5.77%	-99.36%	-6.03%	-5.69%
Operating Cash Flow Q/Q Growth	-3.64%	6.73%	69.49%	-17.77%	-1.04%	15.36%	1.55%	-379.82%	126.99%	-20.02%
Free Cash Flow Firm Q/Q Growth	-94.67%	303.43%	5.98%	-38.56%	-135.12%	95.26%	32.69%	-6.58%	144.50%	167.06%
Invested Capital Q/Q Growth	16.88%	-1.76%	-2.17%	-3.28%	4.17%	1.48%	-2.56%	3.25%	-1.08%	-10.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	52.92%	53.09%	32.96%	40.72%	37.27%	36.31%	37.34%	30.60%	32.75%	34.62%
EBITDA Margin	26.19%	27.86%	9.29%	7.03%	15.21%	15.02%	16.82%	10.71%	12.15%	11.65%
Operating Margin	20.07%	21.86%	-1.03%	2.13%	8.48%	7.72%	9.36%	-1.88%	1.01%	1.80%
EBIT Margin	20.41%	22.48%	4.13%	1.65%	9.10%	7.52%	9.21%	-2.11%	0.75%	1.25%
Profit (Net Income) Margin	13.17%	16.63%	5.31%	2.06%	7.98%	6.83%	7.84%	-3.26%	-1.31%	-4.94%
Tax Burden Percent	64.54%	74.07%	133.85%	128.69%	88.08%	89.10%	83.72%	64.93%	37.87%	178.28%
Interest Burden Percent	99.94%	99.86%	96.16%	96.93%	99.52%	102.01%	101.64%	238.18%	-462.76%	-221.96%
Effective Tax Rate	35.46%	25.93%	-33.85%	-28.69%	11.92%	10.90%	16.28%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	24.37%	29.40%	-3.09%	4.17%	9.53%	7.99%	9.60%	-1.31%	0.45%	0.93%
ROIC Less NNEP Spread (ROIC-NNEP)	24.17%	29.00%	-27.52%	7.21%	7.56%	8.16%	9.61%	-11.51%	-2.78%	-11.38%
Return on Net Nonoperating Assets (RNNOA)	-16.10%	-19.22%	10.48%	-1.83%	-1.88%	-1.96%	-2.99%	-2.70%	-1.86%	-6.68%
Return on Equity (ROE)	8.27%	10.17%	7.39%	2.34%	7.65%	6.03%	6.61%	-4.01%	-1.41%	-5.76%
Cash Return on Invested Capital (CROIC)	0.97%	23.53%	-128.32%	8.03%	-9.06%	6.14%	15.25%	-110.00%	1.23%	16.77%
Operating Return on Assets (OROA)	11.94%	12.81%	4.84%	1.50%	7.03%	5.53%	6.65%	-1.50%	0.38%	0.69%
Return on Assets (ROA)	7.70%	9.48%	6.24%	1.87%	6.16%	5.03%	5.66%	-2.32%	-0.67%	-2.74%
Return on Common Equity (ROCE)	8.27%	10.17%	7.39%	2.34%	7.65%	6.03%	6.61%	-4.01%	-1.41%	-5.76%
Return on Equity Simple (ROE_SIMPLE)	7.76%	9.56%	5.73%	2.28%	7.34%	5.78%	6.38%	-3.55%	-1.40%	-5.99%
Net Operating Profit after Tax (NOPAT)	44	61	-18	38	95	87	103	-30	16	30
NOPAT Margin	12.95%	16.19%	-1.38%	2.74%	7.47%	6.88%	7.84%	-1.32%	0.71%	1.26%
Net Nonoperating Expense Percent (NNEP)	0.20%	0.40%	24.43%	-3.03%	1.97%	-0.17%	-0.01%	10.20%	3.24%	12.30%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-0.80%	0.43%	0.85%
Cost of Revenue to Revenue	47.08%	46.91%	67.04%	59.28%	62.73%	63.69%	62.66%	69.40%	67.25%	65.38%
SG&A Expenses to Revenue	24.36%	23.57%	23.38%	22.86%	21.87%	22.34%	22.99%	26.68%	26.86%	26.82%
R&D to Revenue	4.60%	3.41%	3.97%	3.78%	3.84%	3.38%	3.61%	4.08%	3.78%	3.72%
Operating Expenses to Revenue	32.85%	31.22%	33.99%	38.59%	28.79%	28.59%	27.98%	32.49%	31.74%	32.82%
Earnings before Interest and Taxes (EBIT)	70	85	53	23	115	96	121	-48	17	30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	89	106	120	98	193	191	221	244	274	277
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.11	3.65	3.63	3.72	2.81	3.00	3.12	1.81	1.13	1.93
Price to Tangible Book Value (P/TBV)	3.28	3.81	4.17	4.20	3.41	3.54	3.64	0.00	0.00	0.00
Price to Revenue (P/Rev)	5.27	6.34	3.36	3.36	3.06	3.54	3.83	1.66	1.07	1.59
Price to Earnings (P/E)	40.05	38.14	63.34	163.41	38.29	51.80	48.88	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.50%	2.62%	1.58%	0.61%	2.61%	1.93%	2.05%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.03	9.12	4.37	4.82	3.30	3.71	4.28	1.48	1.08	1.70
Enterprise Value to Revenue (EV/Rev)	4.17	5.17	3.16	3.10	2.82	3.23	3.40	2.29	1.68	2.13
Enterprise Value to EBITDA (EV/EBITDA)	15.94	18.57	34.06	44.10	18.57	21.49	20.19	21.36	13.80	18.29
Enterprise Value to EBIT (EV/EBIT)	20.45	23.01	76.67	188.08	31.02	42.93	36.87	0.00	223.80	170.59
Enterprise Value to NOPAT (EV/NOPAT)	32.22	31.94	0.00	113.37	37.81	46.91	43.31	0.00	237.00	168.70
Enterprise Value to Operating Cash Flow (EV/OCF)	22.21	21.82	26.48	27.10	35.08	18.42	16.70	0.00	22.78	24.87
Enterprise Value to Free Cash Flow (EV/FCFF)	807.83	39.90	0.00	58.88	0.00	60.99	27.28	0.00	87.23	9.32
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.05	0.02	0.00	0.02	0.00	0.79	0.77	0.81
Long-Term Debt to Equity	0.00	0.00	0.05	0.02	0.00	0.00	0.00	0.78	0.74	0.78
Financial Leverage	-0.67	-0.66	-0.38	-0.25	-0.25	-0.24	-0.31	0.23	0.67	0.59
Leverage Ratio	1.07	1.07	1.18	1.25	1.24	1.20	1.17	1.73	2.11	2.10
Compound Leverage Factor	1.07	1.07	1.14	1.21	1.24	1.22	1.19	4.11	-9.77	-4.66
Debt to Total Capital	0.25%	0.17%	4.41%	1.60%	0.00%	1.72%	0.00%	44.17%	43.48%	44.61%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	1.72%	0.00%	0.79%	1.49%	1.44%
Long-Term Debt to Total Capital	0.25%	0.17%	4.41%	1.60%	0.00%	0.00%	0.00%	43.38%	41.99%	43.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.75%	99.83%	95.59%	98.40%	100.00%	98.28%	100.00%	55.83%	56.52%	55.39%
Debt to EBITDA	0.02	0.01	0.46	0.21	0.00	0.14	0.00	6.77	5.95	5.71
Net Debt to EBITDA	-4.20	-4.20	-2.16	-3.69	0.00	-2.08	0.00	5.89	5.02	4.59
Long-Term Debt to EBITDA	0.02	0.01	0.46	0.21	0.00	0.00	0.00	6.65	5.75	5.52
Debt to NOPAT	0.03	0.02	-3.11	0.54	0.00	0.30	0.00	-55.06	102.25	52.63
Net Debt to NOPAT	-8.49	-7.23	14.58	-9.49	0.00	-4.54	0.00	-47.95	86.30	42.37
Long-Term Debt to NOPAT	0.03	0.02	-3.11	0.54	0.00	0.00	0.00	-54.07	98.75	50.93
Altman Z-Score	25.84	35.28	10.79	10.77	9.38	12.36	13.55	1.86	1.63	2.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.85	14.04	4.11	3.72	3.55	4.71	5.13	2.50	2.53	2.59
Quick Ratio	10.19	12.34	2.42	2.24	1.99	2.74	3.35	0.46	0.34	0.33
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1.77	49	-738	74	-90	67	164	-2,516	43	544
Operating Cash Flow to CapEx	683.51%	447.62%	207.34%	202.92%	104.77%	259.53%	391.57%	-69.56%	201.72%	259.49%
Free Cash Flow to Firm to Interest Expense	45.26	416.77	-360.65	104.00	-163.81	0.00	0.00	-37.90	0.46	5.69
Operating Cash Flow to Interest Expense	1,646.03	762.21	75.44	225.97	185.64	0.00	0.00	-0.94	1.75	2.13
Operating Cash Flow Less CapEx to Interest Expense	1,405.21	591.93	39.06	114.61	8.45	0.00	0.00	-2.28	0.88	1.31
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.59	0.57	1.17	0.91	0.77	0.74	0.72	0.71	0.51	0.56
Accounts Receivable Turnover	7.22	6.78	9.82	7.28	6.69	7.79	11.45	13.92	11.79	13.83
Inventory Turnover	3.99	3.83	5.13	2.77	2.45	2.48	2.73	3.21	2.16	2.41
Fixed Asset Turnover	4.26	4.74	5.34	3.37	2.85	2.75	2.82	4.13	3.62	4.51
Accounts Payable Turnover	12.85	12.57	18.66	8.35	6.38	8.08	10.78	10.65	8.30	10.45
Days Sales Outstanding (DSO)	50.57	53.80	37.17	50.12	54.56	46.85	31.89	26.22	30.96	26.39
Days Inventory Outstanding (DIO)	91.40	95.26	71.17	131.89	149.06	147.12	133.90	113.76	168.82	151.65
Days Payable Outstanding (DPO)	28.42	29.03	19.56	43.69	57.23	45.20	33.85	34.26	43.96	34.93
Cash Conversion Cycle (CCC)	113.55	120.03	88.78	138.32	146.39	148.77	131.93	105.72	155.83	143.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	203	215	936	900	1,085	1,105	1,044	3,530	3,502	2,988
Invested Capital Turnover	1.88	1.82	2.25	1.53	1.28	1.16	1.23	1.00	0.64	0.73
Increase / (Decrease) in Invested Capital	42	12	720	-35	184	20	-61	2,486	-27	-514
Enterprise Value (EV)	1,426	1,962	4,089	4,341	3,576	4,103	4,469	5,216	3,787	5,074
Market Capitalization	1,802	2,406	4,348	4,705	3,868	4,500	5,041	3,777	2,408	3,799
Book Value per Share	$36.30	$40.43	$59.52	$61.67	$66.62	$71.60	$76.09	$87.15	$87.96	$80.27
Tangible Book Value per Share	$34.39	$38.71	$51.77	$54.62	$54.88	$60.63	$65.18	($14.26)	($9.10)	($8.51)
Total Capital	581	661	1,254	1,284	1,377	1,529	1,616	3,743	3,757	3,548
Total Debt	1.48	1.11	55	21	0.00	26	0.00	1,653	1,634	1,583
Total Long-Term Debt	1.48	1.11	55	21	0.00	0.00	0.00	1,624	1,578	1,532
Net Debt	-376	-444	-259	-364	-293	-397	-572	1,440	1,379	1,274
Capital Expenditures (CapEx)	9.39	20	74	79	97	86	68	89	82	79
Debt-free, Cash-free Net Working Capital (DFCFNWC)	85	83	354	296	341	341	262	557	541	628
Debt-free Net Working Capital (DFNWC)	462	529	654	678	634	752	829	770	795	937
Net Working Capital (NWC)	462	529	654	678	634	725	829	741	739	886
Net Nonoperating Expense (NNE)	-0.73	-1.65	-86	9.50	-6.47	0.60	0.05	44	46	148
Net Nonoperating Obligations (NNO)	-377	-445	-263	-364	-293	-397	-572	1,440	1,379	1,023
Total Depreciation and Amortization (D&A)	20	20	67	75	77	95	100	292	257	248
Debt-free, Cash-free Net Working Capital to Revenue	24.88%	22.00%	27.40%	21.12%	26.94%	26.81%	19.89%	24.44%	23.93%	26.37%
Debt-free Net Working Capital to Revenue	135.33%	139.33%	50.62%	48.41%	50.05%	59.13%	62.98%	33.79%	35.20%	39.33%
Net Working Capital to Revenue	135.33%	139.33%	50.62%	48.41%	50.05%	57.06%	62.98%	32.48%	32.73%	37.19%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.84	$3.90	$3.50	$1.41	$4.90	$4.16	$4.86	($3.11)	($1.23)	($4.83)
Adjusted Weighted Average Basic Shares Outstanding	15.85M	16.17M	19.61M	20.39M	20.63M	20.91M	21.21M	23.87M	24.09M	24.39M
Adjusted Diluted Earnings per Share	$2.73	$3.66	$3.29	$1.33	$4.69	$4.02	$4.74	($3.11)	($1.23)	($4.83)
Adjusted Weighted Average Diluted Shares Outstanding	16.50M	17.25M	20.86M	21.60M	21.55M	21.59M	21.78M	23.87M	24.09M	24.39M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	16.12M	16.34M	20.24M	20.50M	20.77M	21.14M	23.79M	24.00M	24.14M	24.52M
Normalized Net Operating Profit after Tax (NOPAT)	52	73	51	109	124	121	118	-2.50	33	68
Normalized NOPAT Margin	15.13%	19.33%	3.94%	7.78%	9.78%	9.50%	8.99%	-0.11%	1.48%	2.86%
Pre Tax Income Margin	20.40%	22.45%	3.97%	1.60%	9.06%	7.67%	9.36%	-5.02%	-3.47%	-2.77%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1,788.15	722.73	26.05	32.56	209.94	0.00	0.00	-0.72	0.18	0.31
NOPAT to Interest Expense	1,134.69	520.66	-8.69	54.01	172.25	0.00	0.00	-0.45	0.17	0.31
EBIT Less CapEx to Interest Expense	1,547.33	552.45	-10.33	-78.80	32.75	0.00	0.00	-2.07	-0.69	-0.51
NOPAT Less CapEx to Interest Expense	893.87	350.38	-45.08	-57.35	-4.95	0.00	0.00	-1.80	-0.70	-0.51
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	3.39%	27.32%	5.91%	21.71%	18.45%	14.82%	8.08%	-14.65%	-31.53%	-10.19%

This table displays calculated financial ratios and metrics derived from ICU Medical's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	77.90%	69.74%	4.70%	-2.08%	-7.45%	1.70%	-0.35%	8.58%	6.47%	7.14%
EBITDA Growth	0.78%	43.83%	120.06%	-18.61%	32.91%	-22.47%	-31.36%	0.91%	-17.44%	76.48%
EBIT Growth	-109.19%	-106.59%	121.86%	188.97%	637.55%	-792.58%	-242.41%	242.45%	-64.09%	358.08%
NOPAT Growth	-101.04%	-100.76%	122.28%	5,850.00%	4,993.58%	-5,387.84%	-213.41%	178.70%	-63.96%	-1,181.62%
Net Income Growth	-142.50%	-177.97%	74.23%	-32.91%	154.80%	-10.37%	-302.27%	-115.48%	-555.69%	-38.96%
EPS Growth	-138.46%	-170.33%	74.53%	-32.26%	154.55%	-10.94%	-297.56%	-114.63%	-550.00%	-36.62%
Operating Cash Flow Growth	-97.07%	-102.07%	3,173.40%	97.60%	1,422.78%	5,434.25%	11.02%	5,659.91%	2.66%	-55.96%
Free Cash Flow Firm Growth	-4,936.96%	-3,169.42%	98.81%	97.47%	95.49%	100.76%	380.17%	354.25%	302.50%	2,042.43%
Invested Capital Growth	219.03%	238.05%	1.02%	2.58%	3.57%	-0.78%	-2.51%	-6.12%	-5.89%	-14.68%
Revenue Q/Q Growth	6.57%	-3.32%	-1.62%	-3.40%	0.73%	6.24%	-3.61%	5.26%	-1.23%	6.90%
EBITDA Q/Q Growth	-21.67%	5.64%	7.36%	-8.74%	27.92%	-38.38%	-4.59%	34.15%	4.66%	31.72%
EBIT Q/Q Growth	-147.45%	60.70%	763.71%	-86.22%	1,395.15%	-165.25%	-5.89%	133.15%	56.80%	368.90%
NOPAT Q/Q Growth	-872.92%	52.46%	4,331.98%	-70.62%	728.01%	-153.31%	12.54%	172.19%	7.07%	-1,995.82%
Net Income Q/Q Growth	-76.72%	-17.63%	36.84%	-1.24%	172.86%	-336.90%	-130.19%	45.77%	-54.08%	27.76%
EPS Q/Q Growth	-77.42%	-16.36%	35.94%	0.00%	173.17%	-336.67%	-129.58%	46.01%	-53.41%	28.15%
Operating Cash Flow Q/Q Growth	103.76%	-174.10%	2,510.58%	-103.57%	2,485.41%	159.57%	-49.83%	78.97%	-55.95%	11.34%
Free Cash Flow Firm Q/Q Growth	32.36%	-5.89%	98.84%	-204.21%	-20.68%	117.85%	327.51%	176.07%	-3.88%	88.86%
Invested Capital Q/Q Growth	-1.49%	3.25%	-0.18%	1.04%	-0.55%	-1.08%	-1.92%	-2.70%	-0.32%	-10.32%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	31.18%	30.27%	33.77%	35.01%	33.24%	29.19%	32.69%	34.78%	34.77%	36.08%
EBITDA Margin	10.61%	11.59%	12.70%	12.00%	15.24%	8.84%	8.75%	11.15%	11.82%	14.56%
Operating Margin	-0.08%	-0.04%	1.65%	0.50%	4.13%	-2.07%	-1.88%	1.29%	1.40%	5.98%
EBIT Margin	-0.59%	-0.24%	1.60%	0.23%	3.40%	-2.09%	-2.29%	0.72%	1.15%	5.03%
Profit (Net Income) Margin	-2.21%	-2.69%	-1.73%	-1.81%	1.31%	-2.92%	-6.97%	-3.59%	-5.60%	-3.78%
Tax Burden Percent	61.99%	72.44%	73.28%	43.45%	-134.89%	46.75%	107.35%	109.59%	183.97%	-289.98%
Interest Burden Percent	608.95%	1,559.78%	-146.71%	-1,817.41%	-28.53%	298.88%	282.92%	-453.41%	-265.40%	25.94%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	389.98%
Return on Invested Capital (ROIC)	-0.05%	-0.03%	0.76%	0.23%	1.87%	-0.93%	-0.85%	0.60%	0.67%	-12.74%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.95%	-3.57%	-0.44%	-0.61%	1.25%	-1.54%	-3.15%	-1.35%	-2.18%	-5.62%
Return on Net Nonoperating Assets (RNNOA)	-0.73%	-0.84%	-0.28%	-0.41%	0.87%	-1.03%	-2.11%	-0.89%	-1.43%	-3.30%
Return on Equity (ROE)	-0.78%	-0.86%	0.48%	-0.18%	2.74%	-1.96%	-2.96%	-0.29%	-0.76%	-16.04%
Cash Return on Invested Capital (CROIC)	-105.13%	-110.00%	-0.84%	-2.32%	-2.80%	1.23%	2.59%	6.46%	5.93%	16.77%
Operating Return on Assets (OROA)	-0.38%	-0.17%	0.80%	0.12%	1.73%	-1.06%	-1.18%	0.38%	0.62%	2.79%
Return on Assets (ROA)	-1.43%	-1.92%	-0.86%	-0.92%	0.67%	-1.48%	-3.59%	-1.89%	-3.02%	-2.10%
Return on Common Equity (ROCE)	-0.78%	-0.86%	0.48%	-0.18%	2.74%	-1.96%	-2.96%	-0.29%	-0.76%	-16.04%
Return on Equity Simple (ROE_SIMPLE)	-1.93%	0.00%	-2.19%	-2.29%	-1.34%	0.00%	-2.87%	-3.47%	-5.42%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.33	-0.16	6.58	1.93	16	-8.53	-7.46	5.38	5.77	-109
NOPAT Margin	-0.05%	-0.03%	1.16%	0.35%	2.89%	-1.45%	-1.32%	0.90%	0.98%	-17.35%
Net Nonoperating Expense Percent (NNEP)	2.90%	3.54%	1.20%	0.84%	0.62%	0.61%	2.29%	1.95%	2.84%	-7.12%
Return On Investment Capital (ROIC_SIMPLE)	-	0.00%	-	-	-	-0.23%	-	-	-	-3.08%
Cost of Revenue to Revenue	68.82%	69.73%	66.23%	64.99%	66.76%	70.81%	67.31%	65.22%	65.23%	63.92%
SG&A Expenses to Revenue	25.67%	24.73%	26.83%	27.47%	26.86%	26.30%	27.82%	26.75%	27.62%	25.22%
R&D to Revenue	3.86%	4.06%	3.48%	4.06%	3.77%	3.81%	3.85%	3.92%	3.57%	3.55%
Operating Expenses to Revenue	31.26%	30.31%	32.12%	34.51%	29.11%	31.26%	34.57%	33.49%	33.37%	30.10%
Earnings before Interest and Taxes (EBIT)	-3.50	-1.38	9.13	1.26	19	-12	-13	4.31	6.76	32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	63	67	72	66	84	52	50	67	70	92
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.79	1.81	1.88	2.03	1.37	1.13	1.25	1.42	2.17	1.93
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.76	1.66	1.72	1.87	1.28	1.07	1.15	1.26	1.90	1.59
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.46	1.48	1.53	1.61	1.22	1.08	1.15	1.26	1.72	1.70
Enterprise Value to Revenue (EV/Rev)	2.45	2.29	2.33	2.50	1.92	1.68	1.75	1.82	2.45	2.13
Enterprise Value to EBITDA (EV/EBITDA)	22.36	21.36	18.95	21.33	14.89	13.80	15.72	16.63	24.13	18.29
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	1,896.35	1,040.55	155.10	223.80	0.00	0.00	0.00	170.59
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	888.00	714.34	177.19	237.00	2,037.63	778.17	0.00	168.70
Enterprise Value to Operating Cash Flow (EV/OCF)	225.43	0.00	0.00	142.03	58.93	22.78	23.18	16.52	22.48	24.87
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	87.23	43.87	18.82	28.13	9.32
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.82	0.79	0.78	0.78	0.78	0.77	0.78	0.79	0.78	0.81
Long-Term Debt to Equity	0.81	0.78	0.77	0.76	0.76	0.74	0.76	0.76	0.75	0.78
Financial Leverage	0.25	0.23	0.64	0.67	0.69	0.67	0.67	0.66	0.66	0.59
Leverage Ratio	1.75	1.73	2.15	2.16	2.15	2.11	2.10	2.11	2.09	2.10
Compound Leverage Factor	10.63	26.92	-3.16	-39.17	-0.61	6.31	5.95	-9.55	-5.56	0.54
Debt to Total Capital	45.12%	44.17%	43.95%	43.72%	43.89%	43.48%	43.91%	44.10%	43.79%	44.61%
Short-Term Debt to Total Capital	0.67%	0.79%	0.94%	1.13%	1.39%	1.49%	1.42%	1.44%	1.44%	1.44%
Long-Term Debt to Total Capital	44.44%	43.38%	43.02%	42.60%	42.50%	41.99%	42.49%	42.65%	42.35%	43.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.88%	55.83%	56.05%	56.28%	56.11%	56.52%	56.09%	55.91%	56.21%	55.39%
Debt to EBITDA	7.39	6.77	5.80	6.11	5.66	5.95	6.43	6.37	6.71	5.71
Net Debt to EBITDA	6.28	5.89	5.01	5.38	4.98	5.02	5.43	5.17	5.40	4.59
Long-Term Debt to EBITDA	7.28	6.65	5.68	5.95	5.49	5.75	6.22	6.16	6.49	5.52
Debt to NOPAT	-125.38	-55.06	271.80	204.72	67.40	102.25	833.36	297.93	-329.92	52.63
Net Debt to NOPAT	-106.54	-47.95	234.81	180.08	59.23	86.30	703.93	241.83	-265.32	42.37
Long-Term Debt to NOPAT	-123.51	-54.07	266.01	199.44	65.27	98.75	806.33	288.20	-319.07	50.93
Altman Z-Score	1.80	1.89	1.99	2.07	1.76	1.61	1.67	1.76	2.16	2.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.45	2.50	2.62	2.57	2.63	2.53	2.61	2.41	2.29	2.59
Quick Ratio	0.44	0.46	0.31	0.74	0.78	0.34	0.87	0.89	0.89	0.33
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,347	-2,486	-29	-88	-106	19	81	223	214	405
Operating Cash Flow to CapEx	11.19%	-7.94%	291.46%	-8.72%	164.17%	305.07%	297.19%	425.02%	181.33%	167.26%
Free Cash Flow to Firm to Interest Expense	-131.82	-123.84	-1.28	-3.64	-4.38	0.77	3.40	9.36	8.69	17.26
Operating Cash Flow to Interest Expense	0.13	-0.09	1.83	-0.06	1.45	3.74	1.93	3.44	1.46	1.71
Operating Cash Flow Less CapEx to Interest Expense	-1.03	-1.16	1.20	-0.76	0.57	2.51	1.28	2.63	0.66	0.69
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.65	0.71	0.50	0.51	0.51	0.51	0.52	0.53	0.54	0.56
Accounts Receivable Turnover	12.42	13.92	13.47	12.13	12.01	11.79	15.86	14.68	13.94	13.83
Inventory Turnover	3.04	3.21	2.47	2.28	2.18	2.16	2.12	2.13	2.16	2.41
Fixed Asset Turnover	3.67	4.13	3.55	3.57	3.56	3.62	3.68	3.81	3.89	4.51
Accounts Payable Turnover	10.43	10.65	8.18	8.39	8.50	8.30	8.99	9.65	9.89	10.45
Days Sales Outstanding (DSO)	29.39	26.22	27.10	30.10	30.40	30.96	23.01	24.87	26.19	26.39
Days Inventory Outstanding (DIO)	120.19	113.76	147.92	160.13	167.82	168.82	172.55	171.01	168.64	151.65
Days Payable Outstanding (DPO)	35.01	34.26	44.62	43.49	42.94	43.96	40.58	37.83	36.92	34.93
Cash Conversion Cycle (CCC)	114.57	105.72	130.40	146.74	155.28	155.83	154.98	158.05	157.90	143.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,419	3,530	3,523	3,560	3,541	3,502	3,435	3,342	3,332	2,988
Invested Capital Turnover	0.91	1.00	0.66	0.65	0.65	0.64	0.65	0.67	0.68	0.73
Increase / (Decrease) in Invested Capital	2,347	2,486	35	90	122	-27	-88	-218	-209	-514
Enterprise Value (EV)	5,005	5,216	5,382	5,733	4,315	3,787	3,958	4,198	5,734	5,074
Market Capitalization	3,599	3,777	3,959	4,288	2,872	2,408	2,591	2,893	4,451	3,799
Book Value per Share	$84.22	$87.15	$87.52	$87.88	$86.94	$87.96	$85.37	$83.63	$83.87	$80.27
Tangible Book Value per Share	($15.80)	($14.26)	($13.33)	($11.61)	($9.84)	($9.10)	($9.43)	($8.98)	($8.82)	($8.51)
Total Capital	3,667	3,743	3,748	3,758	3,740	3,757	3,687	3,645	3,644	3,548
Total Debt	1,655	1,653	1,647	1,643	1,641	1,634	1,619	1,607	1,596	1,583
Total Long-Term Debt	1,630	1,624	1,612	1,601	1,589	1,578	1,566	1,555	1,543	1,532
Net Debt	1,406	1,440	1,423	1,445	1,442	1,379	1,367	1,305	1,283	1,274
Capital Expenditures (CapEx)	21	22	14	17	21	30	15	19	20	24
Debt-free, Cash-free Net Working Capital (DFCFNWC)	488	557	562	606	608	541	533	474	448	628
Debt-free Net Working Capital (DFNWC)	735	770	786	803	807	795	785	777	761	937
Net Working Capital (NWC)	710	741	751	761	755	739	732	724	708	886
Net Nonoperating Expense (NNE)	13	15	16	12	8.76	8.62	32	27	39	-85
Net Nonoperating Obligations (NNO)	1,406	1,440	1,423	1,445	1,442	1,379	1,367	1,305	1,283	1,023
Total Depreciation and Amortization (D&A)	67	68	63	65	66	64	63	62	63	60
Debt-free, Cash-free Net Working Capital to Revenue	23.90%	24.44%	24.36%	26.40%	27.05%	23.93%	23.63%	20.57%	19.17%	26.37%
Debt-free Net Working Capital to Revenue	35.99%	33.79%	34.09%	35.02%	35.89%	35.20%	34.77%	33.70%	32.52%	39.33%
Net Working Capital to Revenue	34.78%	32.48%	32.57%	33.17%	33.58%	32.73%	32.45%	31.42%	30.28%	37.19%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.55)	($0.64)	($0.41)	($0.41)	$0.30	($0.71)	($1.63)	($0.88)	($1.35)	($0.97)
Adjusted Weighted Average Basic Shares Outstanding	23.91M	23.87M	24.01M	24.08M	24.13M	24.09M	24.22M	24.39M	24.44M	24.39M
Adjusted Diluted Earnings per Share	($0.55)	($0.64)	($0.41)	($0.41)	$0.30	($0.71)	($1.63)	($0.88)	($1.35)	($0.97)
Adjusted Weighted Average Diluted Shares Outstanding	23.91M	23.87M	24.01M	24.08M	24.37M	24.09M	24.22M	24.39M	24.44M	24.39M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	23.98M	24.00M	24.06M	24.14M	24.14M	24.14M	24.37M	24.43M	24.48M	24.52M
Normalized Net Operating Profit after Tax (NOPAT)	6.89	6.00	14	13	10	-3.81	4.02	17	15	32
Normalized NOPAT Margin	1.15%	1.04%	2.43%	2.44%	1.83%	-0.65%	0.71%	2.87%	2.51%	5.12%
Pre Tax Income Margin	-3.56%	-3.71%	-2.35%	-4.16%	-0.97%	-6.24%	-6.49%	-3.27%	-3.04%	1.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.20	-0.07	0.41	0.05	0.78	-0.50	-0.55	0.18	0.27	1.35
NOPAT to Interest Expense	-0.02	-0.01	0.29	0.08	0.66	-0.35	-0.31	0.23	0.23	-4.66
EBIT Less CapEx to Interest Expense	-1.36	-1.14	-0.22	-0.65	-0.11	-1.73	-1.19	-0.63	-0.53	0.33
NOPAT Less CapEx to Interest Expense	-1.18	-1.08	-0.34	-0.62	-0.22	-1.58	-0.96	-0.58	-0.57	-5.68
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-14.65%	0.00%	0.00%	0.00%	-31.53%	0.00%	0.00%	0.00%	-10.19%

Frequently Asked Questions About ICU Medical's Financials

When does ICU Medical's fiscal year end?

According to the most recent income statement we have on file, ICU Medical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has ICU Medical's net income changed over the last 9 years?

ICU Medical's net income appears to be on a downward trend, with a most recent value of -$117.69 million in 2024, falling from $44.99 million in 2015. The previous period was -$29.66 million in 2023. See ICU Medical's forecast for analyst expectations on what’s next for the company.

What is ICU Medical's operating income?

ICU Medical's total operating income in 2024 was $42.96 million, based on the following breakdown:

Total Gross Profit: $824.78 million
Total Operating Expenses: $781.82 million

How has ICU Medical revenue changed over the last 9 years?

Over the last 9 years, ICU Medical's total revenue changed from $341.67 million in 2015 to $2.38 billion in 2024, a change of 597.2%.

How much debt does ICU Medical have?

ICU Medical's total liabilities were at $2.24 billion at the end of 2024, a 0.7% decrease from 2023, and a 4,667.8% increase since 2015.

How has ICU Medical's book value per share changed over the last 9 years?

Over the last 9 years, ICU Medical's book value per share changed from 36.30 in 2015 to 80.27 in 2024, a change of 121.1%.

Related Companies

This page (NASDAQ:ICUI) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ICU Medical (ICUI) Financials

Frequently Asked Questions About ICU Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ICU Medical (ICUI) Financials

Annual Income Statements for ICU Medical

Quarterly Income Statements for ICU Medical

Annual Cash Flow Statements for ICU Medical

Quarterly Cash Flow Statements for ICU Medical

Annual Balance Sheets for ICU Medical

Quarterly Balance Sheets for ICU Medical

Annual Metrics and Ratios for ICU Medical

Quarterly Metrics and Ratios for ICU Medical

Frequently Asked Questions About ICU Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools